Gut check: could your microbiome be key to obesity and diabetes?
NCT ID NCT07205913
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how gut bacteria are linked to obesity and type 2 diabetes in New Caledonia, where these conditions are very common. Researchers will collect blood, urine, and stool samples from 270 adults to analyze their gut microbes and related chemicals. The goal is to better understand these diseases in this population, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal how gut bacteria influence obesity and diabetes, pointing toward future dietary or probiotic interventions.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health, and findings may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 270 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults living in New Caledonia who are obese with or without type 2 diabetes or healthy
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged between 18 and 60 years. * Ability to understand and provide informed consent. * Ability and willingness to meet the required schedule and study interventions. * Willingness to share their community belonging * Benefit from a social security system. For obese and diabetic patients : * IMC ≥ 30 kg/m² with type 2 diabetes * Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or * Patients with HbA1c ≥ 6.5% (48 mmol/mol) * All stages of albuminuria For obese patients without type 2 diabetes * IMC ≥ 30 kg/m² * Weight stable for at least 2 months * Patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % * No treatment (diabetic or weight loss) * Match age (±5years), sex and self-reported community to the patients from the1 group. For control group : * BMI between 18.5-24.9 kg/m² * Match age (±5years), sex and self-reported community to the patients from the 1 and 2 groups. * Participants with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) and an HbA1c \< 6.5 % Exclusion Criteria: All participants : * Treatment that may alter gastrointestinal motor function, acidity, microbial population, or immunosuppressants * Altered anatomy of the esophagus, stomach, small intestine, or large intestine due to gastrointestinal surgery (except appendectomy or cholecystectomy) * Chronic or acute inflammatory bowel disease or infections * Abdominal or pelvic radiation therapy or abdominal cancer, colorectal cancer * Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing disorders * Organ transplantation and patients receiving immunosuppressive therapy * Severe renal failure and/or patients undergoing dialysis * Cardiovascular, endocrine, renal, or other chronic disease that may affect motility. * Preparation for colon cleansing within the last month * \< 3 bowel movements per week * Women who are pregnant or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise dose best helps kids with metabolic syndrome?
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Can a nurse and a neighbor help tame chronic disease?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?